Surfix Diagnostics

Surfix Diagnostics develops diagnostic tests for the early detection and monitoring of cancer utilizing its photonic diagnostics platform that combines six state-of-the-art technologies. To make it even more exciting: this photonic diagnostics platform is so versatile that it can be used for immunoassays AND for molecular diagnostics. Any protein or nucleic acid-based biomarker in a liquid biopsy can be detected, provided a suitable bioreceptor to capture this biomarker is available. The core of Surfixs photonic diagnostics platform is a photonic biosensor consisting of a photonic biochip and a microfluidic cartridge both optimized with Surfixs proprietary nanocoatings. The biosensor is used...

Biofunctionalization,lab-on-a-chip,diagnostics,point-of-care,photonic biochip,microfluidics,cancer,early detection,and liquid biopsy

Surfix diagnostics operates in the Biotechnology industry.

Surfix diagnostics's revenue is 11m - 100m

Surfix diagnostics has 11 - 50 employees.